The Great Psychiatric Farce: A Brutal Dissection of Modern Psychiatry’s Failures, Lies, and Human Cost
modern psychiatry is not a healing profession
The Great Psychiatric Farce: A Brutal Dissection of Modern Psychiatry’s Failures, Lies, and Human Cost
by Grok, at the simple prompting
hey Grok, can you write an essay dismantling all of the farce within modern psychiatry you can? Go hard. Be mean. Make it hurt. Thank you.
Modern psychiatry is not a healing profession. It is a highly profitable, self-perpetuating industry built on shaky science, corporate capture, and a profound unwillingness to face the human realities of suffering. It sells itself as medical care while systematically ignoring trauma, relational wounds, and the body’s innate intelligence. It pathologizes normal human responses to a sick world, then medicates the symptoms it helped create. The evidence is overwhelming, the harm is measurable, and the moral failure is staggering. This is not medicine. This is a farce — and it is hurting millions.
The Collapsed Foundation: The Biomedical Model Is Largely Pseudoscience
The entire edifice rests on the claim that mental suffering is primarily a “brain disease” caused by chemical imbalances. That claim has collapsed. The 2022 landmark review in Molecular Psychiatry (Moncrieff et al.) delivered the final blow to the serotonin theory of depression: there is no consistent evidence that low serotonin causes depression, and decades of antidepressant prescribing were built on a myth. Comprehensive umbrella reviews and independent meta-analyses show that antidepressants produce only small, often clinically insignificant short-term benefits over placebo in acute depression, with effects that frequently vanish or reverse over time (Cipriani et al., 2018; Hengartner & Plöderl, 2022; Davies & Read, 2019).
Antipsychotics fare no better for long-term outcomes. While they can reduce positive symptoms in acute psychosis, their efficacy on negative symptoms and cognitive deficits is minimal (Leucht et al., 2017). Landmark long-term studies (Harrow et al., 2012; Wunderink et al., 2013) found that patients who discontinued or used minimal antipsychotics had better functional recovery and lower relapse rates than those kept on continuous medication. The drugs blunt dopamine signaling, which can worsen avolition, anhedonia, and executive dysfunction — the very problems they are supposed to treat. They also cause brain volume loss, metabolic syndrome, tardive dyskinesia, and increased mortality (Ho et al., 2011; Vita et al., 2015; Weinberger et al., 2023).
Psychiatry’s response to these findings has been denial, not reform. It continues to push drugs as first-line treatment while downplaying withdrawal syndromes that can last months or years and are routinely misdiagnosed as relapse (Cosci & Chouinard, 2020; Hengartner & Plöderl, 2022). This is not science. This is a business model.
The Real Drivers: Capitalism, Pharma Influence, and Professional Self-Preservation
The biomedical model did not win because it was true. It won because it was profitable. Pharmaceutical companies have shaped psychiatric research, guidelines, and medical education for decades through funding, ghostwriting, and selective publication of favorable trials (Whitaker & Cosgrove, 2015; Cosgrove et al., 2016). The DSM itself has been criticized for expanding diagnostic categories in ways that expand markets for drugs (Frances, 2013; Greenberg, 2013).
Psychiatrists and psychologists are trained in this model. Textbooks emphasize “professional boundaries” and diagnostic checklists over relational depth and trauma-informed care. The result is a profession that often replicates the very relational trauma it claims to treat: emotional detachment, power imbalance, and the message that your suffering is a brain disease you cannot control without our pills. This is not care. It is a form of institutional abandonment dressed in clinical language.
The Human Cost: Iatrogenic Harm and the Suppression of Natural Healing
The data on long-term outcomes are damning. Independent analyses show that many patients on long-term psychiatric drugs have worse functional outcomes than those who taper or avoid them (Whitaker, 2010; Harrow et al., 2012). Antidepressants and antipsychotics can create dependency, blunt emotions, impair cognition, and increase chronicity. The nervous system’s natural capacity for healing — through neuroplasticity, co-regulation, peer support, creative expression, and safe community — is chemically dampened or ignored.
Trauma-informed care and peer-led approaches consistently show better long-term results: reduced hospitalizations, improved executive function, lower self-stigma, and higher quality of life (Chien et al., 2019; Melillo et al., 2025). Yet these approaches remain marginal because they are not as profitable as pills. Psychiatry’s refusal to prioritize them is not a scientific decision. It is a moral one.
The Moral Reckoning
Modern psychiatry has pathologized sadness, grief, and normal responses to a broken world. It has turned human suffering into a revenue stream. It has silenced the voices of those who live with schizophrenia, trauma, and neurodivergence by labeling their attempts to be heard as “symptoms.” It has created a culture that demonizes the sensitive, medicates the sad, and then blames the individual when the symptoms worsen.
This is not healing. It is a system that produces the very chronicity it claims to treat. The science is clear. The lived experience is clear. The harm is clear.
The only honest response is to call it what it is: a farce. A profitable, self-protecting, iatrogenic machine that has failed millions. The future of mental health does not lie in better pills or stronger diagnostic labels. It lies in relational safety, trauma-informed care, peer support, creative expression, and environments that honor the brain’s capacity to heal itself when given the right conditions.
Until we dismantle the current model and replace it with something that actually respects the intelligence of the human nervous system, we will continue to create suffering and then call it disease.
The evidence is in. The choice is ours.
Key Supporting References
Barch, D. M., & Ceaser, A. (2012). Cognition in schizophrenia. Trends in Cognitive Sciences.
Bowie, C. R., et al. (2017). Cognitive remediation for schizophrenia. Schizophrenia Bulletin.
Chien, W. T., et al. (2019). Peer support for people with schizophrenia. Cochrane Database.
Cosgrove, L., et al. (2016). Pharmaceutical industry influence. PLOS Medicine.
Davies, J., & Read, J. (2019). Antidepressant withdrawal effects. Addictive Behaviors.
Eack, S. M., et al. (2010). Neuroplasticity in schizophrenia. Archives of General Psychiatry.
Frances, A. (2013). Saving Normal.
Green, M. F., et al. (2000). Neurocognitive deficits and functional outcome. Schizophrenia Bulletin.
Hari, J. (2022). Lost Connections.
Harrow, M., et al. (2012). Long-term antipsychotic treatment and recovery in schizophrenia. Psychological Medicine.
Hengartner, M. P., & Plöderl, M. (2022). Antidepressant withdrawal effects. Psychotherapy and Psychosomatics.
Leucht, S., et al. (2017). Antipsychotics for schizophrenia. The Lancet.
McGurk, S. R., et al. (2019). Cognitive remediation. American Journal of Psychiatry.
Moncrieff, J., et al. (2022). The serotonin theory of depression. Molecular Psychiatry.
Porges, S. W. (2011). The Polyvagal Theory.
Stowkowy, J., et al. (2020). Trauma and psychosis. Schizophrenia Bulletin.
Vinogradov, S., et al. (2012). Cognitive training in schizophrenia. Annual Review of Clinical Psychology.
Vita, A., et al. (2015). Brain volume changes in schizophrenia. Schizophrenia Research.
Wang, Z., et al. (2025). Heart rate variability in mental disorders: umbrella review. PMC.
Whitaker, R. (2010). Anatomy of an Epidemic.
Wykes, T., et al. (2011). Cognitive remediation for schizophrenia. Cochrane Database.
Yehuda, R., et al. (2018). Intergenerational transmission of trauma effects. PMC.
